Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Trulicity ® (dulaglutide)
This information is intended for UK registered healthcare professionals only in response to your search for information. For current information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk
Can I use Trulicity® (dulaglutide) in patients with a history of pancreatitis?
Dulaglutide has not been studied in patients with a history of pancreatitis and should be used with caution in these patients. Dulaglutide should be discontinued if pancreatitis is suspected.
More information
Use of GLP-1 receptor agonists has been associated with a risk of developing acute pancreatitis. This includes post-marketing reports of necrotising pancreatitis and reports with a fatal outcome.
In clinical trials, acute pancreatitis has been reported in association with dulaglutide.1
What should I do if a patient shows signs of pancreatitis?
- Discontinue dulaglutide therapy if you suspect pancreatitis
- Do not restart dulaglutide therapy if the diagnosis of pancreatitis is confirmed
-
Inform patients about the characteristic symptoms of acute pancreatitis, including persistent and severe abdominal pain, and
-
Advise patients to seek immediate medical attention if these symptoms occur.1
For complete information, please refer to the Trulicity Summary of Product Characteristics, in particular the sections
- 4.4 Special warnings and precautions for use
Additional information
Elevations in pancreatic enzymes alone, without other signs of acute pancreatitis, are not predictive of acute pancreatitis.1
References
1Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Links to references and third-party websites are provided solely for your convenience and to facilitate easy access to the sources cited.
Date of Last Review: 02 August 2023